News

BloodScan 錄取 2026 台灣–柏克萊生醫創新加速器，強化全球商業化布局

BloodScan 榮幸宣布正式錄取 2026 年 Taiwan–Berkeley Health Innovation Accelerator。該計畫為具高度競爭性的國際加速平台，由台灣與柏克萊公衛學院共同推動，致力於支持具高潛力之醫療與生技新創，加速創新技術臨床轉譯與全球商業化發展。

此次入選不僅代表國際對 BloodScan 技術發展方向與市場策略的肯定，也進一步驗證我們在循環腫瘤細胞（CTC）分離與液態切片技術領域的創新價值。

BloodScan 核心技術 Labyrinth One 為自主開發之微流體平台，可在無標記（label-free）條件下高效率分離循環腫瘤細胞（CTC），同時維持細胞活性，支援後續分子分析與功能性研究，應用於轉譯醫學與精準腫瘤學領域。

此一里程碑進一步鞏固 BloodScan 在新世代液態切片技術領域的市場定位，並強化公司推動早期癌症檢測與精準醫療創新的長期願景。

BloodScan is proud to have been recognized as a Top 6 finalist in the Disruptive Technology Award at the ADLM Annual Meeting, highlighting our innovation in next-generation cancer diagnostic technologies.

As part of this recognition, BloodScan was invited to present and showcase its technology at the ADLM exhibition, providing an international platform to demonstrate our advancements in circulating tumor cell (CTC) enrichment and liquid biopsy solutions.

This milestone reflects the strong potential of BloodScan’s proprietary Labyrinth One platform, which enables high-efficiency, label-free CTC isolation while preserving cell integrity for downstream analysis. The recognition from ADLM underscores our commitment to advancing precision oncology and transforming early cancer detection.

We sincerely appreciate ADLM for the opportunity and recognition, and we look forward to continuing our mission of bringing innovative liquid biopsy technologies to global research and clinical applications.

BloodScan is honored to have been selected to present at the Lightning Stage of the J.P. Morgan Healthcare Conference Taipei 2026, where we will showcase our latest advancements in cancer diagnostics.

Leveraging our proprietary Labyrinth Chip technology, BloodScan is advancing a new standard in label-free circulating tumor cell (CTC) enrichment, enabling more efficient approaches for ultra-early cancer detection and precision oncology research.

We sincerely appreciate the opportunity provided by J.P. Morgan and University of California, Berkeley, and are excited to share how BloodScan is contributing to the future of liquid biopsy innovation on a global stage.

This story was originally published by Michigan Engineering News.

Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the University of Kansas suggests.

Of the 2.3 million women with breast cancer today, around a quarter are diagnosed at an early stage where cancer hasn’t spread, called ductal carcinoma in situ, or DCIS.

While these patients tend to have a good prognosis, the cancer can become invasive in 10% to 53% of untreated cases.

With such high stakes, and no accurate way to predict what will happen for any single patient, clinicians recommended that all women with ductal carcinoma in situ receive treatment, which can include lumpectomy or mastectomy.

Radiation therapy is recommended for patients that get a lumpectomy, and patients that test positive for hormone receptor-positive DCIS can also receive anti-hormonal therapy.

“Since early detection can save lives, physicians are now recommending mammograms at younger ages, so more young women have to make some life-altering choices,” said Sunitha Nagrath, the Dwight F. Benton Professor of Chemical Engineering and a co-corresponding author of the study published in Science Advances.

“Currently, patients are often presented with treatment options without adequate information regarding which choice may be most effective based on their individual risk factors.”

Some patients may receive aggressive treatments although their cancer might not have spread. For others, treatment might not be aggressive enough.

Cancer reoccurs within 10 years for around 10% of cases treated with surgery alone, research suggests.

To find methods for discovering the right approach, the National Institutes of Health partly funded the research.

BloodScan 團隊將於 2026 年19-22日參與全球最具指標性的癌症研究盛會之一AACR Annual Meeting 2026，與來自世界各地的頂尖研究機構、臨床專家及生技企業共同交流最新癌症研究與轉譯醫學成果。

本次展會中，BloodScan 將重點展示其核心技術 "Labyrinth One - 循環腫瘤細胞（CTC）自動化富集系統"，致力於提供高效率、高回收率且具細胞活性的 CTC enrichment 解決方案，協助研究人員與臨床團隊加速癌症早期偵測與精準醫療發展。

Labyrinth One 以微流體結構為基礎，優化細胞分離流程，在維持細胞完整性的同時提升檢出效率，適用於多種癌症類型之研究應用，包括頭頸癌、乳癌、肺癌、胰臟癌等泛癌種檢測應用。

我們誠摯邀請全球合作夥伴、研究學者與產業先進蒞臨展位交流，深入了解 BloodScan 如何透過創新技術推動液態切片（liquid biopsy）領域的下一步發展。

展會資訊

• 活動名稱：AACR Annual Meeting 2026

• 時間：2026年4月19-22日

• 地點：San Diego, USA

• 展位資訊：# 1756 (Ground Level)

在臺灣癌症全人關懷基金會董事長謝瑞坤醫師的記憶裡，人生的起點既平凡又單純。家中共有四個孩子，他是長子。父親畢業於中興大學農化系，是當年臺灣農業改良的重要推手，專精於農業改良研究；然而，這個家庭裡沒有醫學背景，也沒有任何人曾走上行醫之路。若依循家族脈絡，他的人生似乎理應與農化或生物科學相關，而非白袍與病房。 

7月24～27日，國家生技研究園區(NBRP)以「護國群山」為策展主題，集結核心設施、合署參展單位及園區進駐/畢業廠商，聯手進軍2025亞洲生技大展。

奇技生命科技(BloodScan Biotech Inc.)才剛在國家生技研究園區招商暨人才與技術媒合會(NBRP Demo Day)的新創PITCH中獲得最佳轉譯獎(translation award)，其是一家致力於精準腫瘤醫學的生物科技公司，專注於液體活檢(Liquid Biopsy)技術的創新與應用。

奇技由美國密西根大學的研發團隊創立並轉移技術，開發Labyrinth One-循環腫瘤細胞(CTC)自動化富集系統，能在短短15分鐘內、無需抗體標記，分離出高純度活體CTC，提高癌症研究與診斷的效率與準確性。

奇技指出，這項技術運用其專利迷宮式微流體技術，克服目前市面上CTC分離方法的限制，例如回收率低、污染高和工作流程繁瑣。不同於錯失間質型CTC的EpCAM系統或採用尺寸過濾方法造成的純度不穩定，Labyrinth One已取得臨床驗證，能捕獲所有CTC表型，回收率高於95%，並有效去除99.9999%背景血細胞。

奇技表示，Labyrinth One目前已完成FDA一類醫材證申請，預計申請二級醫材認證，未來也將申請歐盟CE認證，進攻液體活檢市場，加速將CTC診斷技術落地醫療現場。

今(22)日，2025年國家生技研究園區招商暨人才與技術媒合會(NBRP Demo Day)進入第二日議程，其中舉行新創PITCH擂台，由30組團隊中晉級的16組團隊進行5分鐘短講，從中選出5組團隊/公司獲得獎項，最佳轉譯獎(Translation award)由奇技生物科技獲得、最具影響力獎(Impact award)由安邦生技獲得、前瞻創新獎(Innovation award)由林口長庚紀念醫院褚柏顯實驗室、潛力團隊獎(Potential award)由嘉正生技獲得、投資獎(Investment award)由先知生物科技獲得。

最佳轉譯獎(translation award)：奇技生命科技

奇技生命科技專注於液態活檢技術的創新與應用，透過從密西根大學授權的技術，開發出Labyrinth循環腫瘤細胞(CTC)處理系統，可以無標記、高通量的方式獲取CTC活細胞，並在15分鐘內完成CTC分離，可提高從血液樣本中提取CTC的純度、效率和活性。

奇技生命科技期望能解決傳統腫瘤組織切片的挑戰，Labyrinth循環腫瘤細胞處理系統經與傳統組織切片對比，相似性高達97%，且可在乳管原位癌(DCIS)患者於癌症惡化前檢測到，目前正在學術研究端進行使用，期望明年邁向成為臨床伴隨式診斷。目前，奇技也正在進行pre-A輪300萬美金募資。

Eric Lin, CEO of Bloodscan, shares how his team developed a new system to isolate live circulating tumor cells (CTCs) — without reagents or antibodies.